



**The Drug Utilization Review (DUR) Board Reviewed
the Following New Drug Classes on
February 6, 2018**

Cytokine Modulators, Rheumatoid Arthritis

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Kevzara (Subcutaneous) Injection*.

Cytokine Modulators, Psoriasis

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Siliq (Subcutaneous) Injection* and *Non-Preferred* status with *Prior Authorization* for *Tremfya (Subcutaneous) Injection*.

Antivirals, Hepatitis C Direct-Acting Agents

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Vosevi (Oral) Tablet*.

Antiparkinson Agents

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Xadago (Oral) Tablet*.